[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100608330":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":31,"responsibleParty":47,"collaborators":20,"id":49,"slug":20,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":20,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":20,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":71,"whyStopped":20,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Peking University Cancer Hospital & Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"experimental group","EXPERIMENTAL","Patients meeting inclusion criteria will receive adebrelimab combined with chemotherapy followed by concurrent radiotherapy. Adebrelimab maintenance therapy will be administered until disease progression or intolerable toxicity, for a maximum duration of 2 years.",[13],"Drug: Adebrelimab with concurrent chemoradiotherapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Adebrelimab with concurrent chemoradiotherapy","Adebrelimab combined with chemotherapy and concurrent radiotherapy, followed by maintenance therapy with Adebrelimab until disease progression or intolerable toxicity, for up to 2 years.",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Huiming Yu, MD","CONTACT","010-8819 6984","huiming740512@126.com",{"name":28,"role":24,"phone":29,"phoneExt":20,"email":30},"Leilei Jiang, MD","13810737828","drjiangleilei@163.com",[32],{"facility":33,"status":20,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Peking University Cancer Hospital and Institute","Beijing","Beijing Municipality","100142","China","CN",{"type":40,"coordinates":41},"Point",[42,43],116.39723,39.9075,{"lat":43,"lon":42},[46],{"name":28,"role":24,"phone":29,"phoneExt":20,"email":30},{"type":48,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100608330",false,"NCT07200154","Adebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLC","A Single-arm、Exploratory Study of Adebrelimab in Combination With Chemoradiotherapy Followed by Adebrelimab Maintenance in Patients With Limited-stage Small-cell Lung Cancer","Inclusion Criteria:\n\n* Age 18-75 years, either sex. Histologically or cytologically confirmed limited-stage small-cell lung cancer (LS-SCLC) defined by Veterans Administration Lung Group (VALG) two-stage system.\n\nAvailability of either an archival tumour-tissue block\u002Fslides or a newly obtained biopsy from a lesion that has not previously been irradiated.\n\n≤ 2 prior cycles of chemotherapy or chemotherapy-naïve. ECOG performance-status 0 or 1. At least one measurable lesion per RECIST 1.1: ≥ 10 mm in longest diameter for non-nodal lesions or ≥ 15 mm in short axis for lymph-node lesions on CT scan.\n\nEstimated life expectancy ≥ 3 months. Adequate pulmonary function (as judged by the investigator).\n\nAdequate major organ function defined as:\n\nHaematology: Hb ≥ 90 g\u002FL; ANC ≥ 1.5 × 10⁹\u002FL; PLT ≥ 100 × 10⁹\u002FL. Biochemistry: serum albumin ≥ 30 g\u002FL; ALT and AST \\\u003C 3 × ULN; total bilirubin ≤ 1.5 × ULN; serum creatinine ≤ 1.5 × ULN.\n\nWomen of child-bearing potential must have a negative serum or urine pregnancy test within 14 days before enrolment and must use effective contraception from screening until ≥ 8 weeks after the last study-dose; men must be surgically sterile or agree to use effective contraception during the same period.\n\nVoluntary informed consent signed; willing and able to comply with study procedures and follow-up.\n\nExclusion Criteria:\n\n* Prior solid-organ, allogeneic stem-cell or planned transplantation. Immunosuppressive therapy ≤ 14 days before first adebrelimab dose (except intranasal\u002Finhaled corticosteroids or physiological systemic doses equivalent to ≤ 10 mg\u002Fday prednisolone).\n\nKnown hypersensitivity to etoposide, cisplatin, adebrelimab, their excipients, or severe allergic reaction to any other monoclonal antibody.\n\nLive-attenuated vaccine within 4 weeks before first dose or intent to receive one during the study.\n\nActive autoimmune disease or history of autoimmune disease (e.g., autoimmune hepatitis, interstitial pneumonitis, uveitis, colitis, hypophysitis, vasculitis, nephritis, hyper-\u002Fhypothyroidism).\n\nUncontrolled asthma requiring bronchodilators or other systemic therapy (childhood asthma fully resolved and requiring no intervention in adulthood is allowed).\n\nUrinalysis ≥ ++ protein or 24-h urine protein ≥ 1.0 g. Prior malignancy except adequately treated basal-cell or squamous-cell skin carcinoma or cervical carcinoma in situ.\n\nHIV infection or known AIDS. Within 6 months before enrolment: myocardial infarction, severe\u002Funstable angina, NYHA class ≥ II heart failure, poorly controlled arrhythmia (including QTcF \\> 450 ms \\[men\\] or \\> 470 ms \\[women\\] by Fridericia), symptomatic congestive heart failure.\n\nSystemic anti-infective therapy (IV antibiotics, antifungals, or antivirals) within 4 weeks before first dose, or unexplained fever \\> 38.5 °C during screening or before first dose.\n\nActive hepatitis B (HBV DNA ≥ 500 IU\u002FmL), hepatitis C (anti-HCV positive and HCV-RNA detectable), or HBV\u002FHCV co-infection.\n\nParticipation in another interventional clinical trial within 4 weeks before first dose.\n\nKnown history of substance abuse or recreational drug use. Any severe medical, psychiatric, or laboratory abnormality that, in the investigator's opinion, could increase study-related risk or interfere with results.","ALL","18 Years","75 Years",{"count":59,"type":60},30,"ESTIMATED","INTERVENTIONAL",[63],"PHASE2","This is a single-arm, open-label, single-center phase II trial that will enroll 30 patients with limited-stage small-cell lung cancer to evaluate the safety and efficacy of adebrelimab combined with chemoradiotherapy followed by adebrelimab maintenance.",[66,67],"Limited-stage Small-cell Lung Cancer","Concurrent Chemoradiation Therapy",[69,70,67],"limited-stage small-cell lung cancer","Immune checkpoint inhibitors","NOT_YET_RECRUITING","2025-09-22",{"date":74,"type":75},"2025-09-30","ACTUAL",{"date":74,"type":60},{"date":78,"type":60},"2028-09",{"name":5,"class":6},1]